-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Downgrades Inozyme Pharma to Equal-Weight, Announces $4 Price Target

Benzinga·05/16/2025 22:29:42
Listen to the news
Wells Fargo analyst Tiago Fauth downgrades Inozyme Pharma (NASDAQ:INZY) from Overweight to Equal-Weight and announces $4 price target.